Datopotamab Deruxtecan, often abbreviated as DATO, represents the notable advancement in targeted cancer care. This innovative antibody-drug conjugate combines a monoclonal immunoglobulin specifically focused on HER2 https://www.targetmol.com/compound/datopotamab